Your browser doesn't support javascript.
loading
A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1).
Horrigan, Joseph; Gomes, Tiago Bernardino; Snape, Mike; Nikolenko, Nikoletta; McMorn, Alison; Evans, Stuart; Yaroshinsky, Alex; Della Pasqua, Oscar; Oosterholt, Sean; Lochmüller, Hanns.
  • Horrigan J; AMO Pharma Ltd, Wonersh, Surrey, UK. Electronic address: joe.horrigan@amo-pharma.com.
  • Gomes TB; John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, UK.
  • Snape M; AMO Pharma Ltd, Wonersh, Surrey, UK.
  • Nikolenko N; National Hospital for Neurology and Neurosurgery, Queen Square, University College London Hospitals NHS Foundation Trust, London, UK.
  • McMorn A; AMO Pharma Ltd, Wonersh, Surrey, UK.
  • Evans S; AMO Pharma Ltd, Wonersh, Surrey, UK.
  • Yaroshinsky A; Vital Systems, Inc., Wichita Falls, Texas.
  • Della Pasqua O; Clinical Pharmacology and Therapeutics, University College London, London, UK.
  • Oosterholt S; Clinical Pharmacology and Therapeutics, University College London, London, UK.
  • Lochmüller H; Children's Hospital of Eastern Ontario Research Institute; Division of Neurology, Department of Medicine, The Ottawa Hospital; and Brain and Mind Research Institute, University of Ottawa, Ottawa, Canada.
Pediatr Neurol ; 112: 84-93, 2020 11.
Article en En | MEDLINE | ID: mdl-32942085

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tiadiazoles / Inhibidores Enzimáticos / Glucógeno Sintasa Quinasa 3 beta / Distrofia Miotónica Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tiadiazoles / Inhibidores Enzimáticos / Glucógeno Sintasa Quinasa 3 beta / Distrofia Miotónica Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male Idioma: En Año: 2020 Tipo del documento: Article